Bkrs Pharma Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 23-10-2024
- Paid Up Capital ₹ 4.40 Cr
as on 23-10-2024
- Company Age 12 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 9.25 Cr
as on 23-10-2024
- Satisfied Charges ₹ 1.35 Cr
as on 23-10-2024
- Revenue 19.52%
(FY 2023)
- Profit -5.99%
(FY 2023)
- Ebitda 809.74%
(FY 2023)
- Net Worth 14.80%
(FY 2023)
- Total Assets 43.77%
(FY 2023)
About Bkrs Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 4.40 Cr.
The company currently has active open charges totaling ₹9.25 Cr. The company has closed loans amounting to ₹1.35 Cr, as per Ministry of Corporate Affairs (MCA) records.
Manmohan Bansal, Sumeer Koul, Preeti Bansal, and One other member serve as directors at the Company.
- CIN/LLPIN
U24230HR2012PTC045971
- Company No.
045971
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 May 2012
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Gurugram, Haryana, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Bkrs Pharma?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manmohan Bansal  | Director | 03-Jun-2017 | Current |
| Sumeer Koul | Director | 27-Mar-2014 | Current |
| Preeti Bansal | Director | 28-May-2018 | Current |
| Beenu Koul | Director | 17-May-2012 | Current |
Financial of Bkrs Pharma.
Bkrs Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 19.52% increase. The company also saw a slight decrease in profitability, with a 5.99% decrease in profit. The company's net worth Soared by an impressive increase of 14.8%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bkrs Pharma?
In 2023, Bkrs Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Ukb Agro And Food Private LimitedActive 14 years 6 monthsManmohan Bansal and Preeti Bansal are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 29 Jun 2024 | ₹1.00 Cr | Open |
Sidbi Creation Date: 10 Mar 2023 | ₹7.50 Cr | Open |
Others Creation Date: 20 Sep 2022 | ₹7.50 M | Open |
How Many Employees Work at Bkrs Pharma?
Unlock and access historical data on people associated with Bkrs Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bkrs Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bkrs Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
